Manitol Infomed Fluids (Mannitol)

Mannitol is a sugar alcohol that is not readily reabsorbed by the renal tubules. When administered intravenously, it remains in the extracellular fluid, increasing osmolarity. This osmotic pressure pulls water from cells into the vascular space and renal tubules, enhancing glomerular filtration and urine output while also reducing cerebral edema.

The dosage of mannitol is individualized by the prescribing clinician based on the patient’s weight, renal function, and therapeutic goal. Dosing regimens are determined in a hospital setting and may be adjusted according to response and laboratory monitoring.

Mannitol’s pregnancy category is listed as unknown, and there is limited data on its use in lactating women. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mannitol differs from loop diuretics such as furosemide because it acts osmotically rather than inhibiting sodium‑potassium‑chloride transport. It is particularly useful for rapid reduction of intracranial pressure and for cases where a non‑reabsorbable osmotic agent is needed, whereas loop diuretics are more commonly used for chronic fluid management.

Manitol Infomed Fluids should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and avoid freezing. Ensure the container remains sealed until use.

The product is supplied as a sterile intravenous solution and is administered through a controlled infusion set. Administration is performed by qualified healthcare personnel in a clinical setting, with infusion rates adjusted according to the patient’s condition and monitored vital signs.

Serious risks include acute renal failure, severe electrolyte disturbances (especially hyponatremia or hyperkalemia), pulmonary edema in patients with compromised cardiac function, and rare anaphylactoid reactions. Continuous monitoring of renal function, electrolytes, and fluid balance is essential to mitigate these risks.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe anuria, uncontrolled heart failure, active pulmonary edema, or severe electrolyte imbalances. It should also be used with caution in individuals with recent head trauma or intracranial hemorrhage where rapid shifts in intracranial pressure could be harmful.